Rampant activity of the
hypoxia-inducible factor (HIF)-1 in
cancer is frequently associated with the malignant progression into a harder-to-treat, increasingly aggressive phenotype. Clearly, anti-HIF strategies in
cancer cells are of considerable clinical interest. One way to fine-tune, or inhibit, HIF's transcriptional outflow independently of
hydroxylase activities could be through competing
transcription factors. A CACGTG-binding activity in human
hepatoma cells was previously found to restrict HIF's access to
hypoxia response cis-elements (HRE) in a Daphnia
globin gene promoter construct (phb2). The CACGTG factor, and its impact on
hypoxia-responsive human genes, was analyzed in this study by genome-wide computational scans as well as gene-specific quantitative PCR, reporter and
DNA-binding assays in
hepatoma (Hep3B), cervical
carcinoma (HeLa), and
breast carcinoma (MCF7) cells. Among six
basic helix-loop-helix transcription factors known to target CACGTG palindromes, we identified upstream stimulatory factor (USF)-1/2 as predominant phb2 CACGTG constituents in Hep3B, HeLa, and MCF7 cells. Human genes with adjacent or overlapping HRE and CACGTG motifs included with
lactate dehydrogenase A (LDHA) and Bcl-2/E1B 19 kDa interacting
protein 3 (BNIP3)
hypoxia-induced HIF-1 targets. Parallel recruitment of HIF-1α and USF1/2a to the respective promoter
chromatin was verified for all cell lines investigated. Mutual complementing (LDHA) or moderating (BNIP3) cross-talk was seen upon overexpression or silencing of HIF-1α and USF1/2a. Distinct (LDHA) or overlapping (BNIP3) promoter-binding sites for HIF-1 and USFs were subsequently characterized. We propose that, depending on abundance or activity of its
protein constituents, O(2)-independent USF signaling can function to fine-tune or interfere with HIF-mediated transcription in
cancer cells.